Takemoto Risa, Michihara Seiwa, Han Li-Kun, Fujita Nina, Takahashi Ryuji
Kampo Research Laboratories, Kracie Pharma, Ltd., Toyama, Japan.
Front Nutr. 2021 Feb 4;8:525629. doi: 10.3389/fnut.2021.525629. eCollection 2021.
Kampo medicines are frequently used empirically to treat pain in clinical practice. Ninjin'yoeito (NYT), which is associated with few adverse effects, is often used to treat the elderly, but has not yet been examined in detail. We herein investigated the effects of NYT, at 500 and 1,000 mg/kg p.o. (NYT500/NYT1000 group) in single and repeated administrations for 14 days, on pain in rats with peripheral neuropathy induced by loose ligation of the sciatic nerve (chronic constriction injury: CCI). Untreated CCI rats given distilled water were used as a control group. To assess induced pain, the pain threshold was measured using the von Frey test. To evaluate spontaneous pain, the ground-contact area of the paw with neuropathic pain was measured using the Dynamic Weight Bearing test. Serum samples were collected after the test to elucidate the mechanism of action of NYT, and brain-derived neurotrophic factor (BDNF) and corticosterone protein levels, which have been reported to change due to chronic pain, were analyzed. After single administration of NYT, the pain threshold rose in the NYT500 and NYT1000 groups. The pain threshold tended to rise on day 14 of repeated administration in the NYT500 group ( = 0.08) and it significantly rose at NYT1000 group ( < 0.05) compared to Control group. In addition, the foot contact area increased ( = 0.09). Therefore, CCI-induced pain was significantly remitted and spontaneous pain was remitted after repeated administration of NYT. Serum BDNF levels were higher in untreated CCI rats than in normal rats ( = 0.05), but decreased after the repeated administration of NYT (NYT1000, = 0.15), while serum corticosterone levels were lower ( = 0.12) than those in normal rats and increased after the repeated administration of NYT (NYT1000, = 0.07). The blood BDNF level has been suggested to influence pain intensity. The findings demonstrated NYT effectively treats neuropathic pain, suggesting that a NYT-induced decrease in blood BDNF contributed to the mechanism of pain relief. In addition, the variation of corticosterone was observed, suggesting that normalization of responsiveness to stress by NYT contributed to the pain relief.
汉方药物在临床实践中常凭经验用于治疗疼痛。人参养荣汤(NYT)副作用较少,常用于治疗老年人,但尚未进行详细研究。我们在此研究了NYT以500和1000mg/kg口服给药(NYT500/NYT1000组),单次给药和连续给药14天对坐骨神经松散结扎诱导的周围神经病变大鼠(慢性压迫损伤:CCI)疼痛的影响。给予蒸馏水的未治疗CCI大鼠用作对照组。为评估诱发疼痛,使用von Frey试验测量疼痛阈值。为评估自发疼痛,使用动态负重试验测量有神经性疼痛的爪的地面接触面积。试验后采集血清样本以阐明NYT的作用机制,并分析据报道因慢性疼痛而发生变化的脑源性神经营养因子(BDNF)和皮质酮蛋白水平。单次给予NYT后,NYT500和NYT1000组的疼痛阈值升高。与对照组相比,NYT500组在连续给药第14天疼痛阈值有升高趋势(P = 0.08),NYT1000组显著升高(P < 0.05)。此外,足部接触面积增加(P = 0.09)。因此,连续给予NYT后,CCI诱导的疼痛明显减轻,自发疼痛也得到缓解。未治疗的CCI大鼠血清BDNF水平高于正常大鼠(P = 0.05),但连续给予NYT后降低(NYT1000,P = 0.15),而血清皮质酮水平低于正常大鼠(P = 0.12),连续给予NYT后升高(NYT1000,P = 0.07)。血液BDNF水平已被认为会影响疼痛强度。研究结果表明NYT能有效治疗神经性疼痛,提示NYT诱导的血液BDNF降低有助于缓解疼痛的机制。此外,观察到皮质酮的变化,提示NYT使对应激的反应性正常化有助于缓解疼痛。